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Abstract 23 
The timing of growth in seasonal mammals is inextricably linked to food availability. This is 24 
exemplified in the Siberian hamster (Phodopus sungorus) which uses the annual cycle of 25 
photoperiod to optimally programme energy expenditure in anticipation of seasonal 26 
fluctuations in food resources. During the autumn, energy expenditure is progressively 27 
minimized by physiological adaptations including a 30% reduction in body mass, comprising 28 
of a reduction in both fat and lean tissues. However, the mechanistic basis of this adaptation 29 
is still unexplained. We hypothesised that growth hormone (GH) was a likely candidate to 30 
underpin these reversible changes in body mass. 31 
Administration of pasireotide, a long acting somatostatin receptor agonist developed for the 32 
treatment of acromegaly, to male hamsters in long-day photoperiod (LD) produced a body 33 
weight loss. This comprised of a reduction in lean and fat mass, including kidneys, testes, and 34 
brown adipose tissue typically found in short-day (SD) housed hamsters. Furthermore, when 35 
administered to hamsters switched from SD to LD pasireotide retarded the body weight 36 
increase compared to vehicle treated hamsters. Pasireotide did not alter photoperiod-mediated 37 
changes in hypothalamic energy balance gene expression, but altered expression of Srif 38 
mRNA expression in the periventricular nucleus and Ghrh mRNA expression in the arcuate 39 
nucleus consistent with a reduction in GH feedback and concurrent with reduced serum IGF-40 
1. Conversely, GH treatment of SD hamsters increased body mass which included increased 41 
mass of liver and kidneys. Together these data point to a role for the GH axis in the 42 
determination of seasonal body mass of the Siberian hamster.  43 
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Introduction 44 
Maintenance of endothermy during winter months is a physiological challenge for seasonal 45 
mammals as food resources are diminished when energy requirements are increased by 46 
seasonal environmental changes. Consequently many seasonal mammals have adapted 47 
physiology and behaviours to minimize energy expenditure including a cessation of 48 
reproduction and slowing of growth, but some small mammals can actively reduce body 49 
mass, a change comprised of a reduction in lean, fat, organ and skeletal  masses  (Dehnel’s 50 
phenomenon) (1, 2). In temperate climates photoperiod is the predominant seasonal cue that 51 
anticipates the forthcoming food and climatic environment. The Siberian hamster is an 52 
exemplar of a photoperiodic mammal using seasonal changes in photoperiod to anticipate 53 
food availability (3-5). As autumn approaches, the Siberian hamster reduces body mass 54 
which includes a reduction in the mass of internal organs such as the kidney, liver, adrenal 55 
gland, white adipose tissue, brown adipose tissue, an involution of the reproductive organs 56 
and a reduction in skeletal mass may also occur (6, 7). The winter reduction in body mass of 57 
the Siberian hamster is initiated by a shortening of day length following the summer solstice 58 
and can be simulated in the laboratory by switching hamsters from long day length (LD) to 59 
short day length (SD). Conversely during spring the body mass of the Siberian hamster 60 
increases (8), reversing the reductions of fat mass and lean mass and can be enabled in the 61 
laboratory by switching hamsters from SD to LD (9, 10). 62 
The seasonal physiological adaptations are largely determined by a central mechanism 63 
governed by thyroid hormone (T3) availability to the hypothalamus (11), which in turn 64 
regulates a cohort of genes which contribute to physiological adaptions appropriate for the 65 
season (9, 12-15). Conceptually, the change in body mass during the transition from winter to 66 
summer (SD to LD) could be considered as a growth response. This is supported by evidence 67 
from studies on growth in red deer showing a correlation between growth hormone (GH), 68 
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IGF-1 and seasonal growth (16, 17). Furthermore, mean levels of circulating growth hormone 69 
over a 24h period correlate with photoperiod appropriate body weight in the seasonal rodent, 70 
the golden hamster (Mesocricetus auratus, 18), which might point to a general role for the 71 
GH axis in the regulation of seasonal body size. We therefore hypothesised that hypothalamic 72 
neuroendocrine regulation of GH would be involved in the seasonal body mass cycle of the 73 
Siberian hamster. GH is produced in the pituitary with secretion promoted by growth 74 
hormone releasing hormone (GHRH) from neurons in the arcuate nucleus (ARC) and 75 
inhibited by somatostatin (referred to as somatotropin release-inhibiting factor - SRIF) 76 
produced by neurons of the periventricular nucleus (PeVN). Circulating GH concentration is 77 
regulated by a negative feedback pathway to the hypothalamus, acting to suppress GHRH 78 
stimulated synthesis and secretion. As GH falls, GHRH secretion increases and SRIF 79 
decreases. Through this feedback mechanism, GH is released in a pulsatile manner (19-21). 80 
Interestingly, in the Siberian hamster we and others have shown that Srif expressed in the 81 
ARC is strongly influenced by photoperiod and downstream of central thyroid hormone 82 
balance (10, 14, 15), and so may play a role in the seasonal regulation of the GH axis and 83 
thus seasonal body mass. 84 
Pasireotide is a somatostatin analogue developed for the treatment of acromegaly, which 85 
target somatostatin receptors (SSTRs) at the pituitary to reduce GH secretion (22, 23, 24). 86 
Pasireotide has a high affinity for four of the five somatostatin receptor subtypes with highest 87 
affinity for SSTR5 (SSTR5>2>3>1, 39-fold greater than octreotide, 23). We have utilized 88 
pasireotide to suppress pituitary secretion of GH and assessed the effect on seasonal body 89 
mass and photoperiod regulated hypothalamic gene expression that underpins the 90 
physiological responses of the Siberian hamster. Our data show that GH is a likely proponent 91 
of seasonal body mass regulation, but also provide evidence that somatostatin may play a 92 
broad role in the seasonal regulation of the hypothalamic neuroendocrine axis. 93 
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Materials and Methods 94 
Animals 95 
Animal husbandry and all experiments were in accordance with the German Animal Welfare 96 
Act and approved by the Lower Saxony State Office for Consumer Protection and Food 97 
Safety (ref: 13/1246, 14/1453). Adult male Siberian hamsters were taken from a colony 98 
maintained at the University of Veterinary Medicine, Hannover, having been bred under 99 
natural photoperiod (at 52°N latitude) and ambient temperatures before the summer solstice. 100 
Hamsters were then transferred to artificial long days (LD: 16:8h light:dark; lights on: 04:00-101 
20:00 CET; 20-22°C) after weaning and were a minimum of 3 months old at the start of 102 
experiments. Food (hamster breeding diet, Altromin 7014, Lage, Germany) and water were 103 
available ad libitum, supplemented weekly by a slice of apple. Overhead lighting was 104 
provided by fluorescent tubes (Lumilux LF11, Osram, Germany) resulting in a light intensity 105 
of ca. 200–350 Lux at cage level. During the dark phase, illumination was limited to dim red 106 
light of <5 Lux (Osram, Darkroom red, 15 W). Experimental hamsters were singly housed 107 
indoors throughout all experiments. Hamsters were sacrificed by overdose of CO2 followed 108 
by cervical dislocation. The brain and trunk blood, from which serum was isolated, were 109 
collected and stored at -70°C before use. Organs, epididymal white adipose tissue (EWAT) 110 
and, where applicable, interscapular brown adipose tissue (IBAT) were dissected out and 111 
immediately weighed; testes, kidneys and EWAT were returned to carcasses which were 112 
stored at -70°C and later thawed for body composition analysis by MRI (EchoMRI Whole 113 
Body Composition Analyser, Echo Medical Systems, Houston, Texas).  114 
 115 
LD Experiment 116 
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Sixteen age and weight matched hamsters (3-4 months of age) were maintained in LD, 8 117 
hamsters received  subcutaneously a dose of long acting release (LAR) pasireotide (Novartis, 118 
Basel Switzerland; 160mg/kg based on weight on day of administration) and 8 hamsters 119 
received vehicle (25) only (8 hamsters per day; 4 from each group per day). Twenty-eight 120 
days following the first injection, pasireotide was re-administered and hamsters were 121 
sacrificed at 49 days following first administration. 122 
Switchback Experiment 123 
Thirty-two Siberian hamsters were acclimated to short day photoperiod (SD; 8:16h 124 
light:dark; lights on: 09:00-17:00 CET; 20 ± 1°C) for a period of 10 weeks (69-72 days). One 125 
hamster did not respond to SD and was excluded from the experiment. The hamsters were 126 
divided into four weight matched groups (three groups of 8 and one group of 7). Two groups 127 
(n=8 per group) received a subcutaneous dose of LAR pasireotide (160mg/kg based on 128 
weight on day of administration) or received vehicle only (1 group n=8 and 1 group n= 7). 129 
Injections were carried out over the course of 4 days (8 hamsters per day; 2 from each group 130 
per day) to accommodate consistent killing and retrieval of tissues between 4-5h after lights 131 
off over a 4 day period. One group of hamsters which had received vehicle (SD-vehicle n=7) 132 
and one group which had received pasireotide (SD-pasireotide, n=8) remained in SD. The 133 
remaining vehicle treated (SWB-vehicle, n=8) and pasireotide treated (SWB-pasireotide, 134 
n=8) groups were returned to LD (16:8h light dark). Twenty-eight days following the first 135 
injection, hamsters were re-administered pasireotide or vehicle as appropriate. One SWB-136 
pasireotide hamster had one testis and epididymal fat pad removed due to exposure outside 137 
the body cavity during radiotelemetry implant surgery (data to be reported separately), thus 138 
reducing the sample size to n=7 for EWAT and paired testes mass analyses. Hamsters were 139 
sacrificed at 49 days following first administration. 140 
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 141 
GH Experiment 142 
Siberian hamsters that had been held in SD for 12 weeks were either switched back to LD 143 
(n=6) or administered bovine GH ip. (1mg/kg bovine growth hormone – NIDDK, Bethesda, 144 
MD, USA, catalogue no: AFP-1032SC; in  phosphate buffered saline (PBS) or PBS alone in 145 
200µl doses in the final hour of the light phase, daily for 28d (n=12 per group). GH was 146 
administered at the end of the light phase to extend a possible circadian elevation in GH over 147 
the dark phase, in order to increase the duration of proposed elevated GH which has been 148 
shown to exist in other rodents (18) and be important to interpretation of the GH in LD 149 
Siberian hamsters. A stock preparation of GH was made at 1 mg/ml in PBS under aseptic 150 
conditions, and stored at -20°C in 250µl aliquots. The stock solution was diluted daily at 1 151 
µl/g hamster body mass made up to 200µl with PBS just prior to use.  152 
 153 
Serum glucose and hormone determination 154 
Serum glucose was measured with a glucose monitor and test strips (Accu-Chek, Roche) in 155 
duplicate. Serum IGF-1 (established as a biomarker reflecting circulating GH levels, 26) and 156 
insulin were determined by ELISA (Mercodia, Uppsala, Sweden and R&D Systems, MN, 157 
USA, respectively), following kit instructions for mouse samples. For the insulin ELISA, 158 
samples were diluted 2-fold in sample buffer. 159 
 160 
Riboprobe synthesis 161 
Riboprobes complementary to gene fragments were generated as previously described (11, 162 
27-29). To ascertain possible effects on the sensitivity of the GH-axis by pasireotide 163 
7 
 
treatment, additional riboprobes were synthesised for growth hormone receptor (Gh-r) and 164 
growth hormone releasing hormone (Ghrh); For Gh-r;  primers were F: 5’-165 
AAGTGCGKGTGAGATCCAGACAAC-3’ and R: 5’-166 
GGTACGYCCAGAATCRTCATCCT-3’, based on a consensus between mouse and rat 167 
sequences  (mouse Genbank NM_010284 bases 1066-1089 forward primer and bases 1534-168 
1556 reverse primer). For Ghrh, primers were based on the partial sequence of Mesocricetus 169 
auratus (golden hamster, Genbank NM_001281590) 1. F: 5’-170 
GATGCCACTCTGGGTGTTCTTTG-3’ (bases 26-48), R: 5’-171 
ATCAGGATGGGGGTTTTATTGTAT-3’ (bases 464-441). These primers amplified several 172 
products and therefore a secondary amplification was performed with the original forward 173 
primer and a reverse primer located 3 nucleotides within the target sequence R: 5’-174 
AGGATGGGGGTTTTATTGTATTTA-3’ (bases 461-438). This resulted in the 175 
amplification of a single product of the correct sequence. Templates for riboprobe synthesis 176 
were generated as described previously (10)  177 
In situ hybridisation 178 
Frozen coronal hypothalamic sections were cut at 14µm and mounted on poly-L-lysine 179 
coated slides (ThermoScientific, Rockford, IL, USA). Radiolabelled in situ hybridisation was 180 
carried out as previously described (10). Due to poor tissue preservation ARC region SWB-181 
vehicle sample size was reduced to n=7 and in the pomc experiment SWB-Pasireotide sample 182 
size was reduced to n=7. 183 
Autoradiographic image analysis 184 
Exposed autoradiographic films were scanned at 600 dpi on an Epson scanner linked to a 185 
computer running Image-Pro PLUS analysis software (v4.1.0.0, Media Cybernetics, 186 
Wokingham, USA). Integrated optical density was obtained by reference to a 14C microscale 187 
8 
 
and was determined for three to five sections per slide for each probe, depending on the gene 188 
considered, and the accumulated count taken. Relative integrated optical density (IOD), an 189 
indirect measure of mRNA expression, was expressed relative to the control group (typically 190 
LD-Veh or SD-Veh unless otherwise stated) whose value was defined as 1, and statistical 191 
analysis was carried out on raw IOD values.  192 
Statistical Analysis 193 
All data are expressed as mean ± SEM. Statistical analyses were carried out using Minitab 194 
v.15.0 (Minitab, PA, USA) unless stated otherwise. Data were compared by t-test, assuming 195 
equal variances, one-way or two-way ANOVA as appropriate, with Tukey post hoc 196 
comparisons. Where data did not conform to the assumptions of the test, it was transformed 197 
by log10 or square root, and statistics performed on transformed data (LD experiment: log10: 198 
serum insulin; SWB experiment: log10: serum IGF-1, kidney mass, serum glucose, ARC Gh-199 
r, ARC Srif; square root: ARC Ghrh, ARC Npy; GH experiment: log10: IBAT of 28 day GH 200 
treated hamsters). When data could not be transformed to fit assumptions of the parametric 201 
test, Kruskal-Wallis (KW) and Mann-Whitney (MW) tests were performed as appropriate 202 
(SWB experiment: paired testes mass, Dio3 and ARC Gh-r mRNA expression; GH 203 
experiment: paired testes mass). P-values less than 0.05 were considered statistically 204 
significant. When insulin was measured in the SWB experiment, some samples exceeded the 205 
limit of the assay and so the data were bound from above, with only the upper limit of the 206 
assay being observed rather than the actual value. Therefore a Cox regression was carried out 207 
with Bonferroni correction for multiple testing using the statistical software R and p<0.05 208 
after this correction was considered statistically significant. 209 
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 210 
Results 211 
Short-day-like weight loss in long-day hamsters is induced by somatostatin agonists 212 
To test our hypothesis that the adaptation of SD body mass is a growth related phenomenon, 213 
pasireotide a long-acting somatostatin analogue was administered subcutaneously to hamsters 214 
held in long-day photoperiod (LD) in a 28d slow release particle formula releasing over a 215 
period of 7 weeks. In hamsters treated with pasireotide there was a progressive loss of body 216 
mass (15.0±3.2%, P<0.001 vs vehicle; Fig 1A). The weight loss trajectory in these LD 217 
hamsters was similar to the weight loss trajectory experienced by hamsters transferred from 218 
LD to SD (9,11). Weight loss induced by pasireotide was accompanied by a reduction in lean 219 
mass (P=0.020) and a trend for fat mass reduction (P=0.091) (Fig 1B,C). Analysis of serum 220 
parameters showed pasireotide decreased circulating insulin-like growth factor-1 (IGF-1; 221 
P=0.022, Fig 1D), increased blood glucose concentration (p=0.009, Fig 1F), but had no effect 222 
on serum insulin concentration (Fig 1E). In comparison to vehicle treated hamsters, weight 223 
loss by pasireotide was manifest in tissue mass reductions which included a decrease in 224 
kidney mass (P=0.004), epididymal white adipose tissue mass (EWAT, P=0.010), 225 
interscapular brown adipose tissue mass (IBAT, P=0.006) and paired testes mass (74.7±5.6%, 226 
P<0.001), but liver mass was unchanged (table 1).  227 
Hypothalamic gene expression 228 
 At the level of the hypothalamus, there was no effect of pasireotide on mRNA expression of 229 
Dio2 Srif, Pomc, and Npy expression the ARC or GH-r in either the ARC or PVN (Fig 2A,B; 230 
Supplementary Fig 1A-D). However, Ghrh expression in the ARC was increased by 231 
2.10±0.22 fold by pasireotide treatment (p<0.001) while Srif expression the PeVN was 232 
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decreased to approximately one-fifth of vehicle expression (0.22±0.07 fold, p<0.001, Figure 233 
2C, D). 234 
Pasireotide impairs photoperiod induced weight gain 235 
Hamsters previously acclimated to SD for 10 weeks with a loss of 21% body mass, were 236 
administered pasireotide or vehicle and then switched back (SWB) to LD for 7 weeks or 237 
maintained in SD. Analysis of change in body mass shows there was an effect of photoperiod 238 
and pasireotide with interaction between photoperiod and treatment (Photoperiod: 239 
F(1,27)=83.45 p<0.001; Pasireotide: F(1,27)=21.85, p<0.001; Interaction: F(1,27)=4.75, 240 
p=0.038, Fig 3A), so that after 7 weeks administration, SWB-vehicle hamsters had increased 241 
body mass more than all other groups. More specifically, SWB-vehicle administered 242 
hamsters had regained an average 11.5±1.0g body mass while hamsters administered 243 
pasireotide, growth was restricted to 4.1±1.5g. Overall SWB hamsters gained lean mass, but 244 
this was significantly less in pasireotide hamsters and there was no interaction between 245 
photoperiod and treatment (Photoperiod: F(1,27)=23.82 p<0.001; Pasireotide: F(1,27)=7.01, 246 
p=0.013; Interaction: F(1,27)=1.18, p=0.287, Fig 3B). Similarly, fat mass was increased in 247 
SWB hamsters and suppressed by pasireotide treatment with no interaction (Photoperiod: 248 
F(1,27)=28.06 p<0.001; Pasireotide: F(1,27)=4.83, p=0.037; Interaction: F(1,27)=2.26, 249 
p=0.144, Fig 3C). Serum IGF-1 concentration was increased in SWB hamsters and 250 
suppressed by pasireotide, with SD-pasireotide having significantly lower and SWB-vehicle 251 
having significantly higher concentration compared to all other treatment groups (P<0.05 all 252 
comparisons after Bonferroni correction; Fig 3D). As noted in LD hamsters, there was an 253 
effect of pasireotide to significantly increase serum glucose concentration, independent of 254 
photoperiod (Photoperiod: F(1,27)=1.18 p=0.286; Pasireotide: F(1,27)=4.84, p=0.036; 255 
Interaction: F(1,27)=0.32, p=0.578, Fig 3F). Serum insulin concentration was increased 256 
significantly by SWB to LD (comparisons where p<0.05 after Bonferroni correction: SD-257 
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Vehicle vs. SWB-Vehicle; SD-Pasireotide vs. SWB-Pasireotide; SD-Pasireotide vs. SWB-258 
Vehicle, Fig 3E).  259 
Liver mass was significantly increased in SWB hamsters, but there was no effect of 260 
pasireotide or interaction between photoperiod and treatment (Photoperiod: F(1,27)=29.62 261 
p<0.001; Pasireotide: F(1,27)=2.01, p=0.168; Interaction: F(1,27)=0.80, p=0.378, table 2). 262 
Kidney mass was significantly increased in SWB hamsters, and suppressed by pasireotide 263 
treatment, but there was no interaction between photoperiod and treatment (Photoperiod: 264 
F(1,27)=27.88 p<0.001; Pasireotide: F(1,27)=16.94, p<0.001; Interaction: F(1,27)=0.82, 265 
p=0.374, table 2). EWAT was significantly increased in SWB hamsters with no effect of 266 
pasireotide and no interaction (Photoperiod: F(1,27)=32.45 p<0.001; Pasireotide: 267 
F(1,27)=1.03, p=0.319; Interaction: F(1,27)=1.00, p=0.327, table 2). Similarly, IBAT was 268 
significantly increased in SWB hamsters, with a tendency of pasireotide to decrease IBAT 269 
mass approaching significance, but no interaction between photoperiod and treatment 270 
(Photoperiod: F(1,27)=20.27 p<0.001; Pasireotide: F(1,27)=4.10, p=0.053; Interaction: 271 
F(1,27)=1.81, p=0.189, table 2). Paired testes mass was significantly increased in SWB 272 
hamsters, but there was no overall effect of pasireotide (KW; Photoperiod: p<0.001; 273 
Pasireotide: p=0.115). Within SD there was no effect of pasireotide (MW; p=0.643), but 274 
within SWB hamsters, pasireotide significantly suppressed testes mass (MW: p=0.003 table 275 
2).  276 
Hypothalamic gene expression 277 
Expression of Dio2  was significantly increased by SWB from SD to LD but remained 278 
unaffected by pasireotide treatment with no interaction (Photoperiod: F(1,26)=46.74, 279 
p<0.001; Pasireotide: F(1,26)=0.86 p=0.362; Interaction: F(1,26)=0.51, p=0.482, Fig 4A). 280 
Expression of Dio3 was very low in in the ventricular ependymal layer of SD hamsters and 281 
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was undetectable in any of the SWB hamsters, with no effect of pasireotide (KW; 282 
Photoperiod: p=0.001; Pasireotide: p=0.915. MW within SD p=1.000, Fig 4B) 283 
Expression of Srif in the ARC was significantly reduced in SWB hamsters with no effect of 284 
pasireotide or interaction between photoperiod and treatment (Photoperiod: F(1,26)=17.30, 285 
p<0001; Pasireotide: F(1,26)=0.35 p=0.558; Interaction: F(1,26)=0.16, p=0.694, Fig 4C), but 286 
expression of Srif in the PeVN was significantly reduced by pasireotide treatment, with a 287 
trend towards an effect of short day photoperiod to reduce expression, but no interaction 288 
between photoperiod and treatment (Photoperiod: F(1,27)=2.93, p=0.098; Pasireotide: 289 
F(1,27)=8.37 p=0.007; Interaction: F(1,27)=0.42, p=0.524. Fig 4D).  290 
 291 
Pasireotide significantly increased ARC Ghrh independently of photoperiod (SD-Pasireotide 292 
1.95±0.31 fold change; SWB-Vehicle: 1.12±0.31 fold change; SWB-Pasireotide: 2.98±0.34 293 
fold change. Photoperiod: F(1,26)=2.75, p=0.109; Pasireotide: F(1,26)=19.62 p<0.001; 294 
Interaction: F(1,26)=0.76, p=0.391; Fig 4E). 295 
 296 
Expression of Pomc was significantly raised in SWB hamsters but was unchanged by 297 
pasireotide treatment (Photoperiod: F(1,25)=9.87, p=0.004; Pasireotide: F(1,25)=1.45 298 
p=0.239; Interaction: F(1,26)=1.32, p=0.261, Supplemental Fig 2A). Npy expression was not 299 
significantly altered by photoperiod or pasireotide treatment (Photoperiod: F(1,26)=0.01, 300 
p=0.905; Pasireotide: F(1,26)=0.04 p=0.851; Interaction: F(1,26)=0.28, p=0.603, 301 
Supplemental Fig 2B). 302 
 303 
Expression of Gh-r in the ARC or PVN was not significantly altered by photoperiod or 304 
pasireotide (ARC: Photoperiod: F(1,26)=2.83, p=0.104; Pasireotide: F(1,26)=0.03 p=0.860; 305 
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Interaction: F(1,26)=1.14, p=0.296, Supplemental Fig 2C;  PVN: KW; Photoperiod: p=0.665; 306 
Pasireotide:  p=0.604, Supplemental Fig 2D). 307 
 308 
Growth hormone induces body weight increase in SD hamsters 309 
Daily intraperitoneal injection of GH for 28 days in hamsters previously acclimated to SD for 310 
12 weeks with an average 25% (10g) loss of body mass showed a mean increase of 311 
4.15±0.15g. This increase paralleled that observed in a separate cohort of hamsters switched 312 
from SD to LD (SWB, 4.76±0.76g) over the same period of time (SWB and GH P<0.001 vs 313 
vehicle; Fig 5A). Lean mass was significantly increased for GH treated hamsters only 314 
(P=0.023, Fig 5B), whereas fat mass increased only in SWB hamsters (P=0.002, Fig 5C). 315 
Serum IGF-1 concentrations were compared by Cox regression. This analysis showed SWB 316 
hamsters had greater concentrations of circulating IGF-1 compared to both vehicle and GH 317 
treated hamsters (Fig 5D, P<0.05 after Bonferroni correction). The small increase in IGF-1 in 318 
GH treated hamsters was not significant. Serum insulin was significantly raised by GH 319 
treatment (P=0.011) and this was also the case in SWB compared to vehicle hamsters 320 
(P=0.008, Fig 5E).  321 
In GH treated hamsters, growth was accompanied by increased liver mass (P=0.021) and 322 
kidney mass (P=0.026). There was a significant increase in EWAT in SWB hamsters 323 
compared to vehicle and GH (P<0.001 and P=0.014 respectively, table 3), but GH did not 324 
increase EWAT mass relative to vehicle hamsters. IBAT after 4 weeks in LD or following 325 
GH treatment was not significantly different from vehicle hamsters (table 3). As expected, 326 
testes mass was significantly increased in SWB (P<0.001), but in GH treated hamsters the 327 
small increase in testis mass did not reach statistical significance (table 3). 328 
 329 
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Discussion 330 
The Siberian hamster is one of a number of small seasonal mammals that reduce body mass 331 
during winter. Even though this weight loss has been extensively described, the mechanisms 332 
are not understood. Here we provide evidence to support the view that the GH axis is a 333 
potential proponent of the seasonal neuroendocrine axis underpinning this body mass change.  334 
The seasonal adaptation of reproductive organ regression and recrudescence is well 335 
established in the Siberian hamster, but less well known are the photoperiod-mediated 336 
changes in the mass of internal tissues.  Seasonal changes in organ mass were first described 337 
in the common shrew (Sorex araneus) by Dehnel (referred to as Dehnel’s phenomenon; 1,2). 338 
Although several previous studies on body mass regulation of the Siberian hamster have 339 
demonstrated reduction in muscle and organ mass in short photoperiod (6, 30, 31), with the 340 
exception of adipose tissue and testes mass (32), this is the first report showing that increase 341 
in body mass during increased day length involves increase in mass of those organs which 342 
were reduced during SD exposure. We would therefore consider the Siberian hamster as a 343 
member of a group of mammals that exhibit Dehnel’s phenomenon. 344 
We initiated these studies with the hypothesis that GH underpins the seasonal body weight 345 
changes in the Siberian hamster. Although photoperiod-regulated effects on frequency and 346 
amplitude of pulsatile GH secretion have been previously demonstrated in the golden hamster 347 
(18), due to the pulsatile nature of GH secretion and small size of the Siberian hamster, direct 348 
measurement of GH was not feasible. In the absence of a GH receptor antagonist for use in 349 
rodents, we approached our hypothesis by utilizing pasireotide, a somatostatin receptor 350 
agonist that was developed for the treatment of excess GH production by pituitary 351 
tumours/adenomas (acromegaly) and inhibition of tumour growth (25, 33, 34). This long 352 
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acting somatostatin receptor agonist was delivered in an encapsulated form which steadily 353 
releases the agonist over a period of 28 days.  354 
Pasireotide, when administered to male hamsters in LD, caused a gradual body mass loss 355 
similar to that which can be observed in hamsters transferred from LD to SD photoperiod. 356 
MRI analysis of body composition showed a loss of lean mass which was reflected in a loss 357 
of kidney mass and testes mass both of which occur in response to SD (6, 30, 31). However, a 358 
reduction in liver mass observed in SD hamsters was not obtained.  359 
In this LD paradigm, fat mass determined by MRI showed a trend toward a reduction by 360 
pasireotide. This trend is supported by significantly lower EWAT and IBAT measurement in 361 
pasireotide treated hamsters and is characteristic of hamsters held in SD (7, 35). This may 362 
reflect an involvement of GH or another neuroendocrine pathway in EWAT regulation, but 363 
interestingly pasireotide reveals a neuroendocrine basis for regulating IBAT mass, an 364 
important fat depot in thermogenesis and energy expenditure (36). 365 
As expected, pasireotide treatment resulted in a reduction of circulating IGF-1, which as a 366 
biomarker of endogenous GH is indicative of a suppression of GH secretion (26), a 367 
conclusion which is supported by increased Ghrh expression in the ARC and reduced Srif 368 
expression in the PeVN as a result of reduced GH feedback to the hypothalamus (19-21). 369 
Furthermore in a preliminary experiment with the somatostatin agonist octreotide, a similar 370 
trajectory of body mass loss occurred with terminal liver, kidney and EWAT masses similar 371 
to pasireotide treated hamsters, but only a small effect on paired testis weight (data not 372 
shown).  373 
Pasireotide has highest affinity for SSTR5 (22, 23), thus the effect of pasireotide to reduce 374 
growth would be consistent with data for SSTR5 subtype distribution in the rat pituitary 375 
where SSTR5 is present on 72% of somatotropic cells. A reduction in GH may contribute to 376 
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loss of testicular mass through an action on testicular Leydig cells (37), but the effect of the 377 
somatostatin analogues could also be due in part to antagonism of FSH at testicular Sertoli 378 
cells (38). However, this seems unlikely as the effect on sertoli cells appears to be mediated 379 
by SSTR2 (39). A further possibility is a direct effect of pasireotide on hypothalamic Kiss-1 380 
or Rfrp3 expression, but inaccessibility of somatostatin analogues to the brain renders this 381 
unlikely (see below). A more likely explanation is the inhibition of pituitary LH and FSH 382 
secretion by pasireotide (38), where in the rat 21% of gonadtropes express SSTR5 (40). With 383 
pasireotide treatment, we did not systematically observe for an effect on pelage, but no 384 
striking change in pelage was noted by the end of 7 weeks of treatment. Although in the rat 385 
36% of lactotropes express SSTR5, no effect of pasireotide on prolactin secretion from rat 386 
pituicyte primary cell cultures has been found (41), suggesting prolactin secretion may not be 387 
subject to regulation by somatostatin. However, further analysis of SSTR5 distribution and 388 
other somatostatin receptor subtypes in the hamster pituitary is required to understand the 389 
mechanistic basis for the action of somatostatin and related analogues. 390 
Pasireotide also impaired body mass accretion in hamsters switched from SD (at or close to 391 
the body weight nadir) to LD photoperiod (SWB hamsters). This was reflected in an overall 392 
reduction in lean mass and fat mass in pasireotide treated hamsters. Although measurement of 393 
tissue mass showed no significant effect of pasireotide to suppress tissue regrowth in SWB 394 
hamsters, the 7.4g difference between vehicle and pasireotide treated hamsters is likely to be 395 
due to the sum of differences of tissues which individually have not reached statistical 396 
significance. The exception to this was testes mass. Paired testes mass was increased in SWB 397 
hamsters, but this increase was significantly albeit not completely retarded by pasireotide.  398 
Circulating IGF-1 was increased in SWB-vehicle hamsters but was decreased in both SD and 399 
SWB hamsters treated with pasireotide compared to vehicle treated hamsters indicative of 400 
suppression of pituitary GH secretion. A reduction in GH secretion and reduced GH feedback 401 
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to the hypothalamus by pasireotide is also supported by evidence of increased Ghrh mRNA 402 
expression in the ARC and reduced Srif expression in the PeVN (19,20). The inability of 403 
pasireotide to completely suppress LD physiology in SWB hamsters is likely to be due to 404 
restoration of stimulatory hormones from the hypothalamus, driven by the substantial 405 
increase in Dio2 expression in the hypothalamus (10) competing with the inhibitory action of 406 
pasireotide via SSTR signalling on appropriate neuroendocrine cells of the pituitary. 407 
Pasireotide in both experiments resulted in a small hyperglycaemic response as observed in 408 
humans and rodents (42,43). In hamsters switched from SD to LD, increased insulin was 409 
consistent with previous observation of elevated levels in LD (27,29), but no significant 410 
suppression of serum insulin was found in either experiment after pasireotide treatment, as 411 
reported in human and rodent studies (42,43). However, a suppressive effect on insulin may 412 
have been masked as the hamsters were not fasted prior to taking the terminal blood samples.  413 
 414 
In this study, we found no evidence to suggest pasireotide has an effect on photoperiod gene 415 
expression or central homeostatic mechanisms of energy balance to account for the observed 416 
effect on body and organ masses (31, 44-46).  Therefore the most parsimonious explanation 417 
for the observed effect of pasireotide is an inhibition of GH secretion from the pituitary 418 
gland. This is supported by an observed increase following pasireotide treatment in Ghrh 419 
expression in the ARC and decrease in Srif expression in the PeVN which is consistent with 420 
an inhibition of GH feedback to the homeostatic control of GH output from the pituitary 421 
gland. Additionally, somatostatin and somatostatin analogues are known to have little or poor 422 
accessibility to the brain and may actively be transported from CNS to blood (47-49). 423 
Therefore a direct effect of the analogues in the brain is unlikely and the observed effects are 424 
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more likely to be due to the presence of SSTRs on relevant hormone secreting cells of the 425 
pituitary.  426 
We and Klosen et al (10, 14, 15, 31) have recently demonstrated a robust induction of Srif 427 
expression in the ARC of SD hamsters and we have hypothesised that these neurons may be 428 
important to seasonal growth (10, 14, 31). Klosen et al also showed that in SD hamsters, TSH 429 
reduces Srif expression to the LD state suggesting expression is downstream of photoperiod 430 
mediated change in hypothalamic T3 concentration (15). Unlike Srif expression in the PeVN, 431 
ARC expression was not affected by pasireotide. Consequently, if SRIF neurons in the ARC 432 
are important for seasonal physiological responses including growth, these neurons are 433 
resistant to GH feedback, which might be anticipated for a regulatory system that must reflect 434 
the prevailing photoperiod. 435 
In the context of a broad role for somatostatin in suppressing the seasonal neuroendocrine 436 
axis, it is interesting to note that Srif expression is one of only a small number of genes 437 
showing increased expression in the ARC in SD photoperiod (10). We would hypothesize 438 
that ARC expressing Srif neurons project to the pituitary enabling direct regulation and 439 
possibly setting the tone of GH secretion upon which circadian regulation mediated by SRIF 440 
neurons of the PeVN is imposed. Some support for this hypothesis may be evident in the 441 
reported SD increase in somatostatin content of median eminence of the golden hamster and 442 
the observation of limited projection of SRIF containing ARC neurons to the median 443 
eminence in the dog (50, 51). 444 
Daily GH injections resulted in increased growth of SD adapted Siberian hamsters, reaching 445 
significance compared to SD vehicle control hamsters within 14 days. This growth was in 446 
advance of growth in hamsters switched to LD, the latter not attaining significant difference 447 
until 21 days after SWB. However, both groups finished with the same body mass increase 448 
28 days following application of GH treatment or exposure to LD. Analysis of serum IGF-1 449 
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showed a significant increase in SWB hamsters with several samples exceeding the top 450 
standard in the ELISA assay. This limited the statistical analysis to a Cox regression and 451 
consequently the small increase in IGF-1 as a result of GH injection was not detected as 452 
significant. The response of IGF-1 to GH injection was poor, but it has previously been noted 453 
that IGF-1 may not be a reliable pharmacodynamic marker of exogenous GH treatment in 454 
rodents (52). The increase in body mass was contributed by an increase in both liver and 455 
kidney mass for GH treated hamsters. Changes in these tissues approached significance in 456 
SWB hamsters, and had the hamsters remained in LD for a further 2-4 weeks to recover to 457 
their starting body weight, changes in this group would likely have achieved significance. 458 
The SWB hamsters, however, had significant increases in EWAT, IBAT and testes masses, 459 
none of which were increased by GH treatment suggesting that GH by itself is not involved in 460 
the seasonal regulation of these tissues. 461 
Interestingly, liver mass was unresponsive to pasireotide in either the LD or SWB hamsters, 462 
but did respond to GH treatment in SD hamsters. This may indicate that while a 463 
pharmacological dose of GH is capable of inducing liver growth, regulation of liver mass in 464 
the Siberian hamster is not dependent on endogenous GH or IGF-1. A possible mediator of 465 
liver mass could be seasonal changes in prolactin (31, 53), the latter being regulated by 466 
tuberalin released by the pars tuberalis during summer and suppressed by melatonin during 467 
winter (54, 55) and known to promote normal liver growth, survival and regeneration in 468 
rodents (56). 469 
Summary 470 
Taken together, these data support a view of an involvement of the GH axis in photoperiod 471 
mediated body weight regulation of the Siberian hamster. A previous study in the rat had 472 
shown pasireotide reduced circulating IGF-1 and completely suppressed growth (32).  473 
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Although a direct action of pasireotide on peripheral tissues cannot be ruled out, we would 474 
reason that a reduction in GH underpins the response observed; firstly GH increases lean 475 
mass of SD hamsters, secondly somatostatin would have to act at several different tissues to 476 
reduce or suppress their mass simultaneously in a manner which mimicked the gradual 477 
decline seen SD or increase in LD respectively. A seasonal regulation of the GH axis is 478 
supported by studies in red deer showing a correlation between GH, IGF-1 and seasonal 479 
growth (16, 17) and photoperiod dependent GH secretion in the golden hamster (18). 480 
Therefore our data would extend the concept of a seasonal regulation of the GH axis to both 481 
large and small seasonal mammals. Intriguingly, the effect of pasireotide on multiple 482 
physiological parameters indicates somatostatin may have a broad role in suppressing 483 
multiple neuroendocrine pathways and provides evidence for an involvement of the 484 
neuroendocrine axes in regulating seasonal physiological adaptations that have not hitherto 485 
been considered to be under neuroendocrine regulation (white and brown adipose tissue). 486 
Although further work is required to demonstrate an involvement of GH in other seasonal 487 
mammals that exhibit Dehnel’s phenomenon, (1, 2) our data may explain in part, the 488 
biological basis of this phenomenon. 489 
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Table 1 660 
Tissue (g) Vehicle Pasireotide 
Liver 1.32 ± 0.07 1.25 ± 0.02 
Kidneys 0.41 ± 0.02 0.34 ± 0.01*** 
EWAT 0.69 ± 0.07 0.45 ± 0.04* 
IBAT 0.20 ± 0.01 0.15 ± 0.01** 
Paired Testes 0.76 ± 0.04 0.19 ± 0.04*** 
 661 
  662 
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Table 2 663 
Tissue (g) 
SD  SWB  Result of statistical 
comparison Vehicle Pasireotide Vehicle Pasireotide 
     Photoperiod P < 0.001 
Liver 1.23 ± 0.05 1.19 ± 0.05 1.77 ± 1.11 1.57 ± 0.08 Drug NS 
     Interaction NS  
     Photoperiod P < 0.001 
Kidneys 0.38 ± 0.02 0.32 ± 0.01 0.48 ± 0.02 0.40 ± 0.01 Drug P < 0.001 
     Interaction NS 
     Photoperiod P < 0.001 
EWAT 0.37 ± 0.10 0.21 ± 0.03 0.75 ± 0.08 0.75 ± 0.10 Drug NS 
     Interaction NS  
     Photoperiod P < 0.001 
IBAT 0.11 ± 0.02 0.10 ± 0.01 0.24 ± 0.04 0.15 ± 0.01 Drug NS 
     Interaction NS  
Paired 
Testes 0.13 ± 0.04 0.08 ± 0.02 0.88 ± 0.06 0.51 ± 0.07** 
Photoperiod 
(KW) P < 0.001 
Drug (KW) NS 
 664 
  665 
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Table 3 666 
 667 
Tissue (g) Vehicle GH SWB 
Liver 1.11 ± 0.04 1.36 ± 0.07* 1.37 ± 0.11 
Kidneys 0.32 ± 0.01 0.38 ± 0.01* 0.37 ± 0.02 
EWAT 0.18 ± 0.02 0.26 ± 0.03† 0.41 ± 0.05*** 
IBAT 0.11 ± 0.01 0.12 ± 0.01 0.19 ± 0.04 
Paired Testes 0.06 ± 0.01 0.10 ± 0.02††† 0.51 ± 0.01*** 
 668 
  669 
32 
 
Table legends 670 
Table 1: Terminal tissue masses of LD-Siberian hamsters treated with vehicle or pasireotide 671 
for 49 d. Data are expressed as mean ± SEM. Significant differences signify the effect of 672 
pasireotide on organ mass, compared by paired t-test. *P < 0.05, ** P<0.01, ***P <0.001. 673 
IBAT, interscapular brown adipose tissue; EWAT, epididymal white adipose tissue. All 674 
groups n = 8. 675 
 676 
Table 2: Terminal tissue masses of Siberian hamsters acclimated to SD before switch back to 677 
LD (SWB) or remaining in SD and treatment with pasireotide or vehicle for 49 d. Data are 678 
expressed as mean ± SEM. Statistical comparisons are by 2-way ANOVA or Kruskall-Wallis 679 
tests (KW) as indicated. ** P<0.01 effect of pasireotide within SWB, Mann-Whitney test. 680 
IBAT, interscapular brown adipose tissue; EWAT, epididymal white adipose tissue. SD-681 
Vehicle n = 7, all other groups n = 8.  682 
 683 
Table 3: Terminal tissue mass of SD Siberian hamsters treated with vehicle, pasireotide or 684 
switched back to LD (SWB) for 28 d. Data are expressed as mean ± SEM. Statistical 685 
comparisons are by 1 – way ANOVA with the exception of paired testes mass, compared by 686 
Mann-Whitney tests. † P < 0.05, ††† P < 0.001 compared to SWB. * P < 0.05, *** P < 0.001 687 
compared to Vehicle.  IBAT, interscapular brown adipose tissue; EWAT, epididymal white 688 
adipose tissue; SD, short day photoperiod (8 : 16 h light : dark). Vehicle and GH both n = 12, 689 
SWB n = 6.  690 
  691 
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Figure legends 692 
Figure 1. Pasireotide reduces body mass in LD-acclimated male Siberian hamsters. Change in 693 
body mass (A) of hamsters housed in LD treated with vehicle or pasireotide for 49 days, 694 
statistical differences indicated are between vehicle and pasireotide groups. Overall fat mass 695 
(B) and lean mass (C) of vehicle and pasireotide treated hamsters post dissection, measured 696 
by MRI. Terminal serum IGF-1 (D) and insulin (E) measured by ELISA and serum glucose 697 
(F). Statistical comparison carried out by paired t-test, *P<0.05, **P<0.01, ***P<0.001, n.s.: 698 
not significant. All groups n = 8. Data are all expressed as mean ± SEM. 699 
 700 
Figure 2. Pasireotide does not directly alter photoperiod programmed hypothalamic gene 701 
expression, but does alter mRNA expression stimulated by GH-axis feedback to the 702 
hypothalamus in LD acclimated Siberian hamsters. Relative mRNA expression of Dio2 (A), 703 
Srif (B), and Ghrh (D) in the arcuate nucleus (ARC) and periventricular nucleus (PeVN - D).   704 
Statistical comparisons are by paired t-test; ***p<0.001, n.s.: no significant differences; 705 
example images showing mRNA expression pattern are shown for vehicle and pasireotide 706 
treatments. All groups n = 8. Data are all expressed as mean ± SEM relative to vehicle group 707 
data. Shown is a representative section of the named mRNA expression in the measured 708 
region of the hypothalamus. 709 
 710 
Figure 3. Pasireotide inhibits LD photoperiod driven body mass accretion. Change in body 711 
mass of hamsters treated with vehicle or pasireotide and returned to LD or remaining in SD 712 
photoperiod (A) **p<0.01, ***p<0.001 and different to all other groups, a: p<0.05 SWB-713 
Pasireotide vs SD-Pasireotide; b: p<0.05 SWB-Pasireotide vs both SD groups.  Lean (B) and 714 
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fat (C) mass measured by MRI *p<0.05, ***p<0.001. Terminal serum IGF-1(D); * p<0.05 715 
compared to all groups. Terminal insulin (E); *p<0.05.  Serum glucose (F); *p<0.05. 716 
Statistical comparisons are by 2-way ANOVA with the exception of E, compared by Cox 717 
regression.  SD-Vehicle n = 7, SD-Pasireotide, SWB-Vehicle and SWB-Pasireotide all n = 8; 718 
data are all expressed as mean ± SEM. 719 
 720 
Figure 4. Pasireotide does not directly alter photoperiod programmed hypothalamic gene 721 
expression in SD and SWB hamsters, but does alter mRNA expression stimulated by GH-axis 722 
feedback to the hypothalamus. Relative mRNA expression of Dio 2 (A), Dio 3 (B), Srif (C) in 723 
the arcuate nucleus (ARC),  Srif (D) in the Periventricular nucleus (PeVN)  and of Ghrh (E) 724 
in the ARC. Statistical comparison is by 2-way ANOVA or Kruskal-Wallis and Mann 725 
Whitney tests (B), **p<0.01, ***p<0.001, n.s.: no significant differences; example images 726 
showing mRNA expression pattern are shown for SD and SWB treatments (A-C) or Vehicle 727 
and Pasireotide treatments (D,E). All groups n=8 except for panels A and B: SD-Vehicle n = 728 
7; Panels C, D and E: ARC Srif and Ghrh, SD-Vehicle n = 7, SWB-Vehicle n = 7. Data are 729 
expressed as mean ± SEM, relative to SD-Vehicle.  730 
 731 
Figure 5. Comparison of effect of exogenous bovine GH and LD photoperiod (SWB) on body 732 
mass, and circulating IGF-1 and insulin concentrations in SD Siberian hamsters. Change in 733 
body mass of hamsters previously acclimated to SD before daily administration of GH or 734 
vehicle or switched to LD for 28d; a:P<0.05 Vehicle vs. GH; b:P<0.05 SWB vs. Vehicle (A); 735 
effect on lean mass (B); fat mass (C); terminal serum IGF-1(D) and insulin (E) concentration. 736 
Comparisons are by 1-way ANOVA; *P<0.05, ***P<0.001; Vehicle and GH both n = 12, 737 
SWB n = 6. Data are all expressed as mean ± SEM. 738 
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Supplementary figure 1. Relative mRNA expression in the 
hypothalamus of LD hamsters vehicle or pasireotide 
treated of  Pomc (A), Npy (B), Gh-r (C) in the arcuate 
nucleus (ARC) and Gh-r (D) in the periventricular nucleus 
(PeVN). No significant differences (n.s.) were found, n=8 
for both groups.  
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Supplementary figure 2. Relative mRNA expression in the 
hypothalamus of SD acclimated hamsters remaining in SD or to 
LD (SWB) following administration of either vehicle or 
pasireotide. Pomc (A), Npy (B), Gh-r (C) in the arcuate nucleus 
(ARC) and Gh-r (D) in the periventricular nucleus. **p<0.01, n.s. 
no significant differences; n=8 all groups except SD-vehicle, n=7. 
